Dr. Philip D. Greenberg is the head of Immunology at the Fred Hutchinson Cancer Research Center, and a professor of medicine and immunology at the University of Washington.
Dr. Greenberg is known for his pioneering work in adoptive T cell immunotherapy, which he took from its experimental foundations in the laboratory and brought into the clinic as a treatment for blood cancers. For these contributions, he was awarded the 2011 William B. Coley Award for Distinguished Research in Tumor Immunology and the 2018 Richard V. Smalley, M.D., Memorial Award and Lectureship. Now, Dr. Greenberg is focused on expanding the use of adoptive T cell immunotherapies to other cancers, so that more patients can benefit.
In addition to being a member of CRI’s Scientific Advisory Council, Dr. Greenberg serves on the Postdoctoral Fellowship Review Committee and is a member of CRI’s Clinical Leadership Committee. He is also the editor-in-chief of the CRI-AACR journal Cancer Immunology Research.
Now, we can change T cells to make them function better, make them survive better, make them target the cancer better. The things we’re doing now, we couldn’t even have dreamed about back when I started.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.